Aclaris Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00461U1051

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Tananbaum James B.. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Tananbaum James B. har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
Director, 10% Owner 4.247.670
US:KNTE / Kinnate Biopharma Inc. Director, 10% Owner 0
US:PRDS / Pardes Biosciences Inc President and CEO, Director, 10% Owner 1.000
US: / THESEUS PHARMACEUTICALS INC 10% Owner 1.385.825
US:ACRS / Aclaris Therapeutics, Inc. 10% Owner 8.276
US:GMTX / Gemini Therapeutics Inc Director, 10% Owner 17.245
US:QSI / Quantum-Si incorporated Director 20.512
US:TXG / 10x Genomics, Inc. 10% Owner 2.350.000
US:AERI / Aerie Pharmaceuticals Inc 10% Owner 1.229.633
10% Owner 8.870.820
10% Owner 2.079.569
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Tananbaum James B.. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb ACRS / Aclaris Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ACRS / Aclaris Therapeutics, Inc. Insider Trades
Insidersalg ACRS / Aclaris Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ACRS / Aclaris Therapeutics, Inc. Insider Trades
Insiderkøb QSIAW / Quantum-Si incorporated - Equity Warrant – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

QSIAW / Quantum-Si incorporated - Equity Warrant Insider Trades
Insidersalg QSIAW / Quantum-Si incorporated - Equity Warrant – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

QSIAW / Quantum-Si incorporated - Equity Warrant Insider Trades
Insiderkøb TXG / 10x Genomics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-09-12 TXG Foresite Capital Management I, LLC 187.500 39,0000 187.500 39,0000 7.312.500 365 125 16.125.000 220,51

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TXG / 10x Genomics, Inc. Insider Trades
Insidersalg TXG / 10x Genomics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2020-05-13 TXG Foresite Capital Management I, LLC 800.000 80,1300 800.000 80,1300 64.104.000 9 74.85 -4.224.000 -6,59
2020-05-13 TXG Foresite Capital Management I, LLC 650.000 80,1300 650.000 80,1300 52.084.500
2020-03-17 TXG Foresite Capital Management I, LLC 500.000 59,0000 500.000 59,0000 29.500.000
2020-03-17 TXG Foresite Capital Management I, LLC 250.000 59,0000 250.000 59,0000 14.750.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TXG / 10x Genomics, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Tananbaum James B. som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-05-06 2025-05-06 4 ALMS ALUMIS INC.
Common Stock
P - Purchase 20.000 4.247.670 0,47 4,34 86.800 18.434.888
2025-05-06 2025-05-02 4 ALMS ALUMIS INC.
Common Stock
P - Purchase 25.000 4.227.670 0,59 4,62 115.500 19.531.835
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
P - Purchase 2.187.500 4.202.670 108,55 16,00 35.000.000 67.242.720
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 1.703.998 2.015.170 547,61
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 311.172 311.172
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 311.172 311.172
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 681.598 1.960.337 53,30
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 681.598 1.960.337 53,30
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 311.172 1.278.739 32,16
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 967.567 967.567
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 560.076 1.041.359 116,37
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 560.076 1.041.359 116,37
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 481.283 481.283
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 194.459 194.459
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
P - Purchase 312.500 5.584.889 5,93 16,00 5.000.000 89.358.224
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 1.022.398 5.272.389 24,06
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 622.344 4.249.991 17,16
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 1.122.994 3.067.571 57,75
2024-07-03 2024-07-01 4 ALMS ALUMIS INC.
Common Stock
C - Conversion 1.944.577 1.944.577
2024-06-27 3 ALMS ALUMIS INC.
Common Stock
1.176.470
2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
D - Sale to Issuer -520.711 0 -100,00
2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
D - Sale to Issuer -3.525.957 0 -100,00
2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
D - Sale to Issuer -9.671.643 0 -100,00
2023-08-31 2023-08-31 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
J - Other 1.000 1.000
2023-08-31 2023-08-31 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
D - Sale to Issuer -16.813.146 0 -100,00
2023-07-19 2023-07-17 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
P - Purchase 176.550 1.385.825 14,60 2,97 524.354 4.115.900
2023-07-19 2023-07-17 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
P - Purchase 523.450 4.108.796 14,60 2,97 1.554.646 12.203.124
2023-05-10 2023-05-08 4 KNTE Kinnate Biopharma Inc.
Common Stock
P - Purchase 229.044 520.711 78,53 2,80 641.323 1.457.991
2023-05-10 2023-05-08 4 KNTE Kinnate Biopharma Inc.
Common Stock
P - Purchase 1.550.956 3.525.957 78,53 2,80 4.342.677 9.872.680
2023-04-06 2023-04-05 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
P - Purchase 773.952 8.773.134 9,68 1,50 1.160.928 13.159.701
2023-04-06 2023-04-05 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
P - Purchase 773.952 13.583.762 6,04 1,50 1.160.928 20.375.643
2023-02-22 2023-02-17 4 KNTE Kinnate Biopharma Inc.
Common Stock
J - Other 1.100.000 1.975.001 125,71
2023-01-03 2022-12-29 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
P - Purchase 250.000 1.209.275 26,06 5,00 1.250.000 6.046.375
2023-01-03 2022-12-29 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
P - Purchase 250.000 1.209.275 26,06 5,00 1.250.000 6.046.375
2022-12-05 2022-12-01 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
P - Purchase 637.420 12.809.810 5,24 0,85 541.807 10.888.338
2022-06-13 3 THRX Theseus Pharmaceuticals, Inc.
Common Stock
3.335.346
2022-06-13 3 THRX Theseus Pharmaceuticals, Inc.
Common Stock
959.275
2021-12-30 2021-12-23 4/A PRDS PARDES BIOSCIENCES, INC.
Common Stock
C - Conversion -4.941.250 0 -100,00
2021-12-30 2021-12-23 4/A PRDS PARDES BIOSCIENCES, INC.
Common Stock
C - Conversion 4.941.250 4.941.250
2021-12-28 2021-12-23 4 PRDS PARDES BIOSCIENCES, INC.
Stock Option (right to buy)
A - Award -75.000 75.000 -50,00
2021-12-28 2021-12-23 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
C - Conversion -4.873.750 0 -100,00
2021-12-28 2021-12-23 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
A - Award 7.759.072 7.759.072
2021-12-28 2021-12-23 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
C - Conversion 4.873.750 4.873.750
2021-12-28 2021-12-23 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
A - Award 1.000.000 1.000.000 10,00 10.000.000 10.000.000
2021-12-23 2021-12-22 4 PRDS PARDES BIOSCIENCES, INC.
Common Stock
P - Purchase 325.000 325.000 10,00 3.250.000 3.250.000
2021-11-03 2021-11-01 4 ACRS Aclaris Therapeutics, Inc.
Common Stock
J - Other 8.276 8.276
2021-11-03 2021-11-01 4 ACRS Aclaris Therapeutics, Inc.
Common Stock
J - Other -1.954.904 0 -100,00
2021-10-06 2021-10-04 4 GMTX Gemini Therapeutics, Inc. /DE
Stock Option (Right to Buy)
A - Award 17.245 17.245
2021-06-14 2021-06-11 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 20.512 20.512
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 348.125 1.598.125 27,85 0,00 348 1.598
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 348.125 1.598.125 27,85 0,00 348 1.598
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 1.250.000 1.250.000 10,00 12.500.000 12.500.000
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 1.250.000 1.250.000 10,00 12.500.000 12.500.000
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 743.936 743.936
2021-06-14 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 4.463.619 4.463.619
2021-02-23 2021-02-19 4 FSII FS Development Corp. II
Class A Common Stock
P - Purchase 602.500 602.500 10,00 6.025.000 6.025.000
2021-02-10 3 ACRS Aclaris Therapeutics, Inc.
Common Stock
1.954.904
2021-02-10 3 ACRS Aclaris Therapeutics, Inc.
Common Stock
3.399.034
2021-02-10 3 ACRS Aclaris Therapeutics, Inc.
Common Stock
1.258.243
2021-02-09 2021-02-05 4 GMTX Gemini Therapeutics, Inc. /DE
Common Stock
C - Conversion -2.928.750 0 -100,00
2021-02-09 2021-02-05 4 GMTX Gemini Therapeutics, Inc. /DE
Common Stock
C - Conversion 2.928.750 2.928.750
2021-02-09 2021-02-05 4 GMTX Gemini Therapeutics, Inc. /DE
Common Stock
A - Award 1.500.000 1.500.000 10,00 15.000.000 15.000.000
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series C Preferred Stock
C - Conversion -48.376 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series C Preferred Stock
C - Conversion -145.128 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series C Preferred Stock
C - Conversion -157.222 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series B Preferred Stock
C - Conversion -18.641 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series B Preferred Stock
C - Conversion -55.922 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series B Preferred Stock
C - Conversion -2.666.002 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series A Preferred Stock
C - Conversion -99.488 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series A Preferred Stock
C - Conversion -298.465 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series A Preferred Stock
C - Conversion -6.347.893 0 -100,00
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock
C - Conversion 166.667 291.667 133,33
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock
C - Conversion 500.001 875.001 133,33
2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock
C - Conversion 9.171.643 9.671.643 1.834,33
2020-12-04 2020-12-02 4 KNTE Kinnate Biopharma Inc.
Stock Option (right to buy)
A - Award 40.501 40.501
2020-12-04 2020-12-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
P - Purchase 125.000 125.000 20,00 2.500.000 2.500.000
2020-12-04 2020-12-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
P - Purchase 375.000 375.000 20,00 7.500.000 7.500.000
2020-12-04 2020-12-03 4 KNTE Kinnate Biopharma Inc.
Common Stock
P - Purchase 500.000 500.000 20,00 10.000.000 10.000.000
2020-10-19 2020-08-14 4 FSDC FS Development Corp.
Class A Common Stock
P - Purchase 441.500 441.500 10,00 4.415.000 4.415.000
2020-05-14 2020-05-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
S - Sale -650.000 2.350.000 -21,67 80,13 -52.084.500 188.305.500
2020-05-14 2020-05-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
S - Sale -800.000 3.500.000 -18,60 80,13 -64.104.000 280.455.000
2020-05-14 2020-05-12 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -1.930.198 0 -100,00
2020-05-14 2020-05-12 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 1.930.198 4.300.000 81,45
2020-05-08 2020-05-06 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -1.500.000 3.153.528 -32,23
2020-05-08 2020-05-06 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -500.000 1.930.198 -20,57
2020-05-08 2020-05-06 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 1.500.000 3.000.000 100,00
2020-05-08 2020-05-06 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 500.000 2.369.802 26,74
2020-04-24 2020-04-23 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -1.000.000 2.430.198 -29,15
2020-04-24 2020-04-23 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 1.000.000 1.869.802 114,97
2020-04-24 2020-04-22 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 92.258 327.383 39,24
2020-04-24 2020-04-22 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -178.584 0 -100,00
2020-04-24 2020-04-22 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 178.584 178.584
2020-04-24 2020-04-22 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -700.000 869.802 -44,59
2020-04-15 2020-04-14 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -1.500.000 4.653.528 -24,38
2020-04-15 2020-04-14 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 1.500.000 1.500.000
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 109.849 235.125 87,69
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -21.686 0 -100,00
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 21.686 21.686
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -201.115 0 -100,00
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 201.115 201.115
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -433.725 0 -100,00
2020-04-15 2020-04-13 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -788.317 1.569.802 -33,43
2020-03-26 2020-03-24 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -2.170.619 3.430.198 -38,76
2020-03-26 2020-03-24 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 2.170.619 2.358.119 1.157,66
2020-03-19 2020-03-18 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 125.276 125.276
2020-03-19 2020-03-18 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -241.619 0 -100,00
2020-03-19 2020-03-18 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other 241.619 241.619
2020-03-19 2020-03-18 4 TXG 10x Genomics, Inc.
Class A Common Stock
J - Other -947.079 187.500 -83,47
2020-03-19 2020-03-17 4 TXG 10x Genomics, Inc.
Class A Common Stock
S - Sale -250.000 433.725 -36,56 59,00 -14.750.000 25.589.775
2020-03-19 2020-03-17 4 TXG 10x Genomics, Inc.
Class A Common Stock
S - Sale -500.000 1.134.579 -30,59 59,00 -29.500.000 66.940.161
2020-03-19 2020-03-04 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -683.725 6.153.528 -10,00
2020-03-19 2020-03-04 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion -1.447.079 5.600.817 -20,53
2020-03-19 2020-03-04 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 683.725 683.725
2020-03-19 2020-03-04 4 TXG 10x Genomics, Inc.
Class A Common Stock
C - Conversion 1.447.079 1.634.579 771,78
2020-03-02 2020-02-27 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -271.767 1.229.633 -18,10 17,07 -4.639.063 20.989.835
2020-03-02 2020-02-27 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -425.457 1.925.020 -18,10 17,07 -7.262.551 32.860.091
2020-03-02 2020-02-27 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -302.776 1.369.938 -18,10 17,07 -5.168.386 23.384.842
2019-12-23 2019-12-20 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -289 0 -100,00
2019-12-23 2019-12-20 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 28.900 1.501.400 1,96 30,00 867.000 45.042.000
2019-12-05 2019-12-03 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -266 289 -47,93
2019-12-05 2019-12-03 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 26.600 1.472.500 1,84 30,00 798.000 44.175.000
2019-12-05 2019-11-26 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -44 555 -7,35
2019-12-05 2019-11-26 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 4.400 1.445.900 0,31 30,00 132.000 43.377.000
2019-11-18 2019-11-15 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -199 599 -24,94
2019-11-18 2019-11-15 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 19.900 1.441.500 1,40 30,00 597.000 43.245.000
2019-11-18 2019-11-14 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -57 798 -6,67
2019-11-18 2019-11-14 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 5.700 1.421.600 0,40 30,00 171.000 42.648.000
2019-11-12 2019-11-07 4 AERI AERIE PHARMACEUTICALS INC
Put Option (obligation to purchase)
X - Other -150 855 -14,93
2019-11-12 2019-11-07 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
X - Other 15.000 1.415.900 1,07 30,00 450.000 42.477.000
2019-11-05 3/A AERI AERIE PHARMACEUTICALS INC
Common Stock
1.672.714
2019-11-05 3/A AERI AERIE PHARMACEUTICALS INC
Common Stock
1.950.477
2019-11-05 3/A AERI AERIE PHARMACEUTICALS INC
Common Stock
870.445
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion 6.837.253 6.837.253
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Class B Common Stock
C - Conversion 7.047.896 7.047.896
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Series C Convertible Preferred Stock
C - Conversion -1.324.195 0 -100,00
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Series B Convertible Preferred Stock
C - Conversion -5.513.058 0 -100,00
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Series C Convertible Preferred Stock
C - Conversion -558.260 0 -100,00
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.002.166 0 -100,00
2019-09-16 2019-09-16 4 TXG 10x Genomics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -5.487.470 0 -100,00
2019-09-16 2019-09-12 4 TXG 10x Genomics, Inc.
Class A Common Stock
P - Purchase 187.500 187.500 39,00 7.312.500 7.312.500
2019-09-06 2019-09-05 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 15.700 2.350.477 0,67 18,42 289.194 43.295.786
2019-09-06 2019-09-04 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 90.900 1.400.900 6,94 18,48 1.679.832 25.888.632
2019-09-06 2019-09-04 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 9.300 2.334.777 0,40 18,48 171.864 43.146.679
2019-09-04 2019-09-03 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 15.100 2.325.477 0,65 21,45 323.895 49.881.482
2019-09-04 2019-09-03 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 34.900 2.310.377 1,53 20,54 716.846 47.455.144
2019-09-04 2019-08-30 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 25.000 2.275.477 1,11 21,36 534.000 48.604.189
2019-08-23 2019-08-23 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 38.300 2.250.477 1,73 23,42 896.986 52.706.171
2019-08-23 2019-08-22 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 6.700 2.212.177 0,30 23,68 158.656 52.384.351
2019-08-23 2019-08-21 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 1.153 2.205.477 0,05 23,25 26.807 51.277.340
2019-08-20 2019-08-20 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 50.000 2.204.324 2,32 23,21 1.160.500 51.162.360
2019-08-20 2019-08-19 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 3.847 2.154.324 0,18 23,34 89.789 50.281.922
2019-08-20 2019-08-16 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 100.000 2.150.477 4,88 24,23 2.423.000 52.106.058
2019-08-14 2019-08-14 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 100.000 2.050.477 5,13 23,73 2.373.000 48.657.819
2019-08-14 2019-08-13 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 178.903 1.310.000 15,82 25,52 4.565.605 33.431.200
2019-08-14 2019-08-13 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 71.097 1.131.097 6,71 24,92 1.771.737 28.186.937
2019-08-14 2019-08-12 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 189.555 1.060.000 21,78 24,43 4.630.829 25.895.800
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.166.350
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
6.444.113
2019-08-14 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.364.081
2017-05-31 2017-05-26 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -10.182 1.950.477 -0,52 55,95 -569.683 109.129.188
2017-05-31 2017-05-26 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -9.818 1.672.714 -0,58 55,95 -549.317 93.588.348
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.325.723
2017-05-31 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
5.603.850
2016-10-11 2016-10-06 4/A AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -25.187 1.672.697 -1,48 40,34 -1.016.041 67.476.430
2016-10-11 2016-10-06 4/A AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -24.813 1.647.901 -1,48 40,34 -1.000.954 66.476.162
2016-10-07 2016-10-06 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -25.187 1.672.697 -1,48 40,34 -1.016.041 67.476.430
2016-10-07 2016-10-06 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
S - Sale -24.813 1.647.901 -1,48 40,34 -1.000.954 66.476.162
2016-10-07 3/A AERI AERIE PHARMACEUTICALS INC
Common Stock
1.672.714
2016-10-07 3/A AERI AERIE PHARMACEUTICALS INC
Common Stock
1.697.884
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
8.870.820
2016-08-19 3 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
5.837.940
2016-07-26 2016-07-22 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
P - Purchase 250.000 1.697.884 17,27 17,50 4.375.000 29.712.970
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.793.312
2016-07-26 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
4.568.482
2016-06-02 2016-05-31 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
S - Sale -120.000 4.202.920 -2,78 15,23 -1.827.360 64.002.066
2016-06-02 2016-05-31 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
S - Sale -120.000 235.020 -33,80 15,23 -1.827.360 3.578.885
2015-08-26 2015-08-24 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
P - Purchase 25.485 355.020 7,73 19,65 500.900 6.977.812
2015-08-11 2015-08-11 4 AIMT Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -3.775.400 0 -100,00
2015-08-11 2015-08-11 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
P - Purchase 17.035 329.535 5,45 20,50 349.199 6.755.105
2015-08-11 2015-08-11 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
P - Purchase 312.500 312.500 16,00 5.000.000 5.000.000
2015-08-11 2015-08-11 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
P - Purchase 312.500 312.500 16,00 5.000.000 5.000.000
2015-08-11 2015-08-11 4 AIMT Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value
C - Conversion 3.775.400 3.775.400
2013-10-16 2013-06-24 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 4.817 2.079.569 0,23 6,77 32.594 14.071.196
2013-10-16 2013-06-14 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 7.500 2.074.752 0,36 7,46 55.962 15.480.970
2013-10-16 2013-06-12 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 5.700 2.067.252 0,28 7,45 42.483 15.407.643
2013-10-16 2013-06-03 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 10.000 2.061.552 0,49 6,99 69.908 14.411.898
2013-10-16 2013-05-22 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 5.005 2.051.552 0,24 6,74 33.729 13.825.614
2013-10-16 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 1.811 2.046.547 0,09 6,84 12.380 13.990.605
2013-10-16 2013-05-20 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 8.120 2.044.736 0,40 6,90 56.048 14.113.790
2013-10-16 2013-05-17 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock
P - Purchase 36.616 2.036.616 1,83 6,77 247.953 13.791.353
2013-10-16 3 AMBI AMBIT BIOSCIENCES CORP
Common Stock
2.000.000
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)